英矽智能押注AI能设计出有效药物；rentosertib进入IIa期后，港交所上市

做的是什么生意

Insilico Medicine builds the Pharma.AI platform (PandaOmics for target discovery, Chemistry42 for molecule design) and runs its own clinical pipeline, led by the TNIK inhibitor rentosertib (ISM001-055) for idiopathic pulmonary fibrosis.

启动资金：Reuters reported a $255M financing in June 2021; $110M Series E led by Value Partners (Mar 2025) at a unicorn valuation; HKEX IPO raised HKD 2.277 billion (Dec 2025).

起因

Founded in the US in 2014 by Alex Zhavoronkov, Insilico Medicine spent its early years publishing AI-for-biology research — a 2019 Nature Biotechnology paper showed its GENTRL model generating a DDR1 inhibitor in 21 days. It then bet the company on end-to-end generative drug discovery: target discovery, molecule design and clinical development all driven by its Pharma.AI platform.

经过

In 2019 PandaOmics flagged TNIK as a novel IPF target; Chemistry42 designed ISM001-055, and the preclinical candidate was nominated in February 2021, 18 months after target identification. Phase 0 and two Phase I trials (New Zealand and China) showed safety, and in February 2023 the drug received FDA Orphan Drug Designation. In March 2024 Nature Biotechnology published the full journey from target to Phase II. The China Phase IIa (NCT05938920) enrolled 71 patients across 21 sites; in September 2024 Insilico reported positive preliminary results, and in November 2024 the topline showed a dose-dependent FVC improvement — +98.4 mL at 60 mg once daily versus a decline in the placebo arm — with a favorable safety profile, while a parallel US Phase IIa (NCT05975983) also read out positive.

结果

In March 2025 Insilico closed a $110M Series E led by Value Partners at a unicorn valuation; on December 30, 2025 it listed on the HKEX main board (03696.HK), raising HKD 2.277 billion in the year's largest Hong Kong biotech IPO, with the public tranche oversubscribed about 1,427 times and cornerstones including Lilly, Tencent and Temasek. On July 7, 2026 the renamed rentosertib entered a Phase III trial (320 patients across 47 Chinese sites) — the first AI-discovered-target, AI-designed-molecule drug to reach late-stage testing.

可借鉴之处

平台押注需要人体试验的证据点：英矽智能的独角兽故事只有当IIa期FVC数据验证了AI发现的靶点和AI设计的分子后才变得可信。